RIGEL PHARMACEUTICALS INC 8-K

What Happened
Rigel Pharmaceuticals (RIGL) announced on July 1, 2026 (8-K filing) that Alison L. Hannah, M.D. was appointed Executive Vice President and Chief Medical Officer, and that she resigned from the company’s Board of Directors effective July 1, 2026. Dr. Hannah had been a Board member since May 2021 and brings decades of oncology drug development experience. The filing also discloses that Lisa Rojkjaer, M.D. ceased serving as Rigel’s Executive Vice President and Chief Medical Officer and separated from the company effective June 25, 2026.

Key Details

• Appointment effective: Alison L. Hannah named Executive VP & Chief Medical Officer, effective July 1, 2026.
• Board change: Dr. Hannah resigned from Rigel’s Board of Directors effective July 1, 2026; she had served on the Board since May 2021.
• Prior CMO departure: Lisa Rojkjaer, M.D. ceased serving as Executive VP & CMO and separated from Rigel effective June 25, 2026.
• Background: Dr. Hannah has consulted in pharma/biotech since 2000 and previously served as Chief Medical Officer of CytomX Therapeutics and Senior Medical Director at SUGEN, Inc.

Why It Matters
This 8-K reports leadership changes in Rigel’s clinical and medical strategy leadership—appointing an experienced oncology drug-development executive as CMO while she leaves the Board. For investors, this affects company governance (a director departure) and executive leadership overseeing clinical programs; the filing contains no financial terms or compensation details and does not indicate changes to guidance or reported results.